Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a

Freedom from disease activity in multiple sclerosis

(2015) E. Havrdova et al.   NEUROLOGY

MRI correlates of disability progression in patients with CIS over 48 months

(2014) Tomas Uher et al.   NeuroImage-Clinical

Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis

(2013) Alberto Gajofatto et al.   DISEASE MARKERS

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

(2013) Bianca Weinstock-Guttman et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

(2013) Angela Vidal-Jordana et al.   Multiple Sclerosis Journal

Clinical impact of early brain atrophy in clinically isolated syndromes

(2013) F Pérez-Miralles et al.   Multiple Sclerosis Journal

Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model

(2013) Michael G. Dwyer et al.   NEUROIMAGE

Assessing treatment response to interferon- : Is there a role for MRI?

(2013) R. Dobson et al.   NEUROLOGY

Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study

(2013) Dana Horakova et al.   PLoS One

Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis

(2013) Robert Zivadinov et al.   RADIOLOGY

Early predictors of non-response to interferon in multiple sclerosis

(2012) D. Horakova et al.   ACTA NEUROLOGICA SCANDINAVICA

Corpus Callosum Atrophy – A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study

(2012) M. Vaneckova et al.   EUROPEAN NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

(2012) Virginia Devonshire et al.   LANCET NEUROLOGY

Scoring treatment response in patients with relapsing multiple sclerosis

(2012) MP Sormani et al.   Multiple Sclerosis Journal

Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis

(2012) A. Giorgio et al.   NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study

(2012) Tomas Kalincik et al.   PLoS One

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

The predictive value of gray matter atrophy in clinically isolated syndromes

(2011) M. Calabrese et al.   NEUROLOGY

Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes

(2009) M Di Filippo et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal

Callosal lesion predicts future attacks after clinically isolated syndrome

(2009) N. Jafari et al.   NEUROLOGY

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

(2008) R. Zivadinov et al.   NEUROLOGY